SILENCE CANCER ONCE AND FOR ALL
BLOCK THE GENES THAT CAUSE CANCER
WE WANT TO HEAR FROM YOU
FOR MORE INFORMATION ON OUR NEWLY DISCOVERED TARGETED CANCER CELL THERAPY
KOP THERAPEUTICS EXPANDS CANCER RESEARCH IN CANADA
Targeted Oncogene Silencing Technology for Numerous Cancers
KOP Therapeutics is a biotechnology company headquartered in Vancouver, BC Canada, in partnership with Thomas Jefferson University — Sidney Kimmel Cancer Center located in Philadelphia, Pennsylvania, U.S.A.
KOP Therapeutics expands the cancer research and commercialization of it’s newly discovered KOP Genomic Drug Platform, a cell-based Antisense Oligonucleotide (AON) Cancer Therapy in Canada.
Targeted Low Toxicity Oligonucleotide Therapy for Prostate Cancer
KOP Therapeutics’ unique and novel drug design targets biomolecules generated on the cell surface of most cancers including those cells that are resistant to current cancer therapies. Leaving the normal healthy cells intact, the KOP Drug is designed to treat cancer by targeting, blocking and silencing the cancer genes with minimal side effects and preventing cancer recurrences. With the alarming escalation of new cancer cases in 2021 estimated at 1,700,000 in the US alone, KOP Therapeutics is committed to finding the solution through financing the development and commercialization of our KOP Targeted Cell Based Cancer Therapy Platform.
FIND OUT MORE
KOP Scientific Advisory Board
Partnering with world experts in cancer biology
Dr. Mathew L Thakur
Professor of Radiology,
Radiation Oncology & Urology,
Thomas Jefferson University
Dr. Eric Wickstrom
Professor of Biochemistry &
Thomas Jefferson University
SECURITIES LAWYER: GREGORY CHU, A. LAW CORPORATION
650-1188 GEORGIA STREET, VANCOUVER, BC V6E 4A2 TEL: 604.628.5005 GTCHU@TELUS.NET
IP LAWYER: THEODORE SUM, PARTNER SMART & BIGGAR/FETHERSTONHAUGH
2300-1055 WEST GEORGIA STREET, VANCOUVER, BC V6E 3P3 TEL: 604.682.7780 TWSUM@SMART-BIGGAR.CA
KOP THERAPEUTICS' NOVEL AI-ENABLED DRUG DESIGN PLATFORM
KOP-101 MECHANISM OF ACTION
DRUG BINDS AND ENTERS THE CELL
KOP-101 Drug Kills malignant cells and spares the normal cells.
KOP-101 Drug Silences the Cancer
The KOP Drug Platform is designed to treat cancer by targeting, blocking and silencing particular cancer genes with minimal side effects and preventing recurrences.
We anticipate the KOP-101 P Drug to successfully target many more tumor types but if necessary can streamline more drugs as stated below.
DISCOVER THE POWER OF PHILANTHROPY AND SUPPORT OUR RESEARCH WITH THOMAS JEFFERSON UNIVERSITY — SIDNEY KIMMEL CANCER CENTRE
“KOP Therapeutics’ strategic alliance and partnership with TJU & SKCC redefines tomorrow’s cancer care with world renowned scientific experts, Dr. Mathew Thakur and Dr. Eric Wickstrom revolutionary scientific breakthroughs further developed into novel therapies. Your transformational gift goes directly to Thomas Jefferson University and applied to Dr. Thakur and Dr. Wickstrom Research Fund.
KOP Therapeutics Corp.
501-815 Hornby Street
Vancouver, BC V6Z 2E6,
The information contained in this presentation is in summary form only, is not intended to be complete and may contain inadvertent or unintentional errors. No representation, warranty or guarantee, expressed or implied, is made as to the fairness, accuracy or completeness of information contained herein, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, results or statements in relation to future matters contained in this presentation. This presentation does not constitute an offer to sell or the solicitation of an offer to buy any security and is not intended to be relied upon as advice to investors or potential investors. KOP is not liable to any recipient or third party for the use of or reliance on the information contained in this presentation.
This communication contains forward-looking statements, which relate to future events or future performance, that are neither promises nor guarantees and are subject to numerous risks and uncertainties that may cause future results to differ materially from those expected and does not constitute an offer to sell or a solicitation of an offer to buy any securities. KOP’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), or any state securities laws and may not be offered or sold within the United States or to or for the account or benefit of a U.S. person (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws or an exemption from such registration is available.
Also, this communication is intended for the sole use of the addressee(s) and may contain confidential, personal and/or privileged information. Unless you are the intended, recipient, we ask that you do not retain, disclose, distribute, or take action relying on any information contained herein, and that you please alert us immediately of the erroneous delivery by return e-mail. Any communication received in error, or subsequent reply should be deleted or destroyed. Thank you for your cooperation.
COPYRIGHT AND TRADEMARK
KOP Therapeutics, 501-815 Hornby Street Vancouver, BC V6Z 2E6, Canada